drugset / Trial / NCT00706836
PharmacofMRI of Anxiolytic Medications (Pregabalin)
Phase 4
Completed
16 enrolled
University of California, San Diego
National Institute of Mental Health (NIMH) · collab
RandomizedCrossoverSingle-blindDiagnostic
Summary
The purpose of this study is to use functional magnetic resonance imaging (fMRI) in healthy controls to examine the acute effects of certain anxiolytic medications on brain function. In this case, the medication pregabalin will be used. The investigators hypothesize that pregabalin (at doses of 50 mg and 200 mg, versus placebo) will yield a reduction in amygdala and insula activity (in a dose-dependent fashion) during emotion processing using fMRI.
Timeline
- Start
- 2008-06
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pregabalin | Small molecule | 50 mg | Oral |
| Comparator | Pregabalin | Small molecule | 200 mg | Oral |